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Gestational trophoblastic diseases (GTD) comprise a range of
interrelated tumours including partial and complete hydatidiform
moles, and choriocarcinoma. These tumours all arise from tissue
of placental origin and due to their exquisite chemosensitivity are
curable even in the presence of widespread metastases. Placental
site trophoblastic tumour (PSTT) is a rare form of GTD. This clin-
ical and pathological entity was first described in 1976 (Kurman et
al, 1976) when the term ‘trophoblastic pseudotumour’ was used to
describe a disease which followed a benign clinical course. It soon
became apparent that those cases in the original report were not
wholly representative of the disease spectrum and that this tumour
did indeed have a malignant potential (Twiggs et al, 1981), leading
to the proposal of the current nomenclature (Scully and Young,
1981). It is important to make the distinction between PSTT and
other forms of GTD, as the former tumour is less chemosensitive
and adverse outcomes are more common. Patients typically
presented with abnormal bleeding per vaginum following a time
period of amenorrhoea (Finkler, 1991; Bower et al, 1996), though
a wide range of other presenting symptoms have been reported
including galactorrhoea, virilization (Nagelberg and Rosen, 1995),
nephrotic syndrome (Young et al, 1985; Bower et al, 1996) and
polycythaemia (Brewer et al, 1992). Approximately 100 cases
have been described in the English language literature and we now
report our own series of seven consecutive cases.
METHODS
We have conducted a retrospective analysis of all cases of PSTT
managed at the Sheffield Trophoblastic Disease Centre from 1984
to 1996. Patients were identified from a computer database.
During this time we received 4988 registrations for GTD and
managed seven cases of PSTT, reflecting the rarity of this condi-
tion relative to other forms of GTD. Case records were traced and
details were obtained of the clinical features and treatment
received by each patient. In addition the histological features of
each tumour were reviewed.
RESULTS
The results of each case in our series is summarized in Table 1.
Clinical features
The median age of the patients in this series was 37 years (range
26–52). The antecedent pregnancy in six cases was a full-term
pregnancy; five females and one male. In the other case (patient
6) there were no previously documented pregnancies prior to the
diagnosis of PSTT. In the six patients who had a previously
documented pregnancy the median interval from pregnancy to
diagnosis of PSTT was 24 months (range 12 months to 13
years). Irregular bleeding per vaginum and/or amenorrhoea
were the presenting features in 6/7 cases; the other patient
presenting in clinical shock with an acute abdomen following
uterine perforation.
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At presentation, 3/7 patients had disease confined to the uterus. A
further two patients had pulmonary metastases only. The other two
patients had vaginal vault and widespread metastases respectively.
The median beta human chorionic gonadotrophin (bhCG) at diag-
nosis was 314 iu l–1 (range 6–107, 600 iu l).
Pathology
The pathology of all cases was reviewed, though in case 4 only a
single haematoxylin and eosin (H&E) section, of a metastasis to
the ovary, could be traced. Hysterectomy specimens showed a
poorly circumscribed tumour with variable haemorrhage or
necrosis, sometimes confined to the endometrial aspect. On
histological examination the tumours were characterized by
gross nuclear and cytoplasmic pleomorphism of intermediate
trophoblast cells. The cells infiltrated freely between muscle
fibres and characteristically replaced vessel walls. Mitotic counts,
necrosis and staining for hCG and hPL are shown in Table 1. The
tumour in case 4 was predominantly mononuclear cells resem-
bling atypical cytotrophoblast and intermediate trophoblast, with
extensive necrosis but no biphasic pattern of mutually arranged
cytotrophoblast and syncytiotrophoblast. The diagnosis is consid-
ered to be more like placental site trophoblastic tumour than
choriocarcinoma. Figures 1, 2 and 3 respectively show the gross
specimen, H&E stain and hPL staining in case 5, as a typical
example of this tumour.
Treatment and outcome
The three patients with disease confined to the uterus at diagnosis
were all treated surgically with total abdominal hysterectomy
(with ovarian conservation in 2/3 cases). None required
chemotherapy and all are alive and well with no evidence of
disease.
The two patients who had pulmonary metastases only are also
alive and well with no evidence of disease. In neither case was the
diagnosis of PSTT made prior to commencement of therapy (‘low
risk’ in one ‘high risk’ in the other, see Table 2). Patient 5 devel-
oped drug-resistant disease after four cycles of ‘high risk’ MAE
chemotherapy and underwent a hysterectomy. A histological diag-
nosis of PSTT was then made and the patient received a further
five cycles of CEC salvage chemotherapy (see Table 2). Follow-up
has been ongoing for 5 years. Patient 7 was originally treated with
a working diagnosis of low-risk GTD with low-dose intramuscular
(i.m.) methotrexate. However, when the results of immunohisto-
chemical staining were known (see below) this diagnosis was
changed to PSTT. CEC salvage chemotherapy was administered
with a complete response (follow-up 3 years).
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Table 1 Clinical features, histological details, treatment and outcome in seven patients with PSTT
Patient reference 1 2 3 4 5 6 7
Age (years) 37 26 38 43 34 52 27
Antecedent Female Female twins Female Female Female No previously Male
pregnancy FTND FTND FTND FTND documented FTND
pregnancy




Presenting symptoms Amenorrhoea Ruptured uterus IBPV IBPV Amenorrheoa Amenorrhoea IBPV
IBPV
hCG at registration 10 6 314 107 600 2525 107 1575
(iu l–1)
Number of 0 0 1 Multiple Multiple 0 Multiple
metastases




Treatment TAH TAH TAH/RT D/C D/C TAH D/C
MTX MAE MAE BSO D/C
Etoposide CEC/IT MTX TAH MTX
Surgery Cranial Irradiation CEC CEC
MAE
MTX
Outcome A W NED A W NED DOD DOD A W NED A W NED A W NED
Duration of follow-up 9 10 20 2 6 3 3
(years)
Pathological features:
mitoses/10 hpf (2 mm2)5 2 1 5 1 4 1 1 5
% hPL 80 70 70 ND 10–20 90 10
% hCG 5 <5 5 ND < 5 5 50
Necrosis – – ++ ++ – + ++
AW, Alive and well; BSO, Bilateral salpingo-oopherectomy; CEC, Cyclophosphamide/etoposide/cisplatin; CNS, Central nervous system; D/C, Dilatation and
curettage; DOD, Died of disease; FTND, Full-term normal delivery; hCG, Human chorionic gonadotrophin; hpf, High power field; hPL, Human placental
lactogen; IBPV, Irregular bleeding per vaginum; IT, Intrathecal; MAE, Methotrexate/dactinomycin/etoposide; MTX, Methotrexate; ND, Not done; NED, No
evidence of disease; RT, Radiotherapy; TAH, Total abdominal hysterectomy.1188 AM Gillespie et al
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The two patients who died with PSTT both had metastatic
disease at commencement of therapy at the treatment centre.
Patient 3 had a particularly complicated history. Following a
hysterectomy in 1968 performed for irregular vaginal bleeding a
histological diagnosis of choriocarcinoma was made – though this
was felt to be atypical in type. Pelvic radiotherapy was given.
Sixteen years later in 1984 she presented to us with a vaginal vault
recurrence, and on this occasion the histopathological diagnosis
was PSTT. Retrospective histological analysis confirmed this
diagnosis in the original tumour. She received four cycles of i.m.
methotrexate and eight cycles of intravenous etoposide. She
relapsed again in 1986 (given four cycles of MAE chemotherapy,
see Table 1), in 1987 (further palliative surgery) and in 1988 (pallia-
tive methotrexate); she died of neutropenic sepsis in association
with progressive disease. Patient 4 was originally considered to be
a case of choriocarcinoma with widespread metastases at diagnosis.
Subsequent histopathological evaluation re-classified the tumour 
as PSTT (see Discussion). She was initially treated with the
methotrexate, dactinomycin, etoposide regimen. However, drug-
resistant disease developed and salvage chemotherapy (cisplatin,
etoposide, cyclophosphamide) was instituted. In addition the
patient received cranial irradiation for intracerebral metastases. A
complete response was never achieved and the patient died 2 years
after diagnosis. Disseminated PSTT was found at autopsy.
DISCUSSION
The establishment of National and Regional Centres for the
screening and treatment of trophoblastic diseases has led to the
optimization of treatment for those with most forms of GTD.
However, PSTT is so uncommon that even those centres treating
large numbers of women with GTD will rarely treat women with
this condition. The rarity of this tumour and its varied biological
behaviour means there is no consensus on optimal treatment
strategies. Our series re-emphasizes many issues raised by other
authors.
Figure 1 Case 5 hysterectomy. Placental site trophoblastic tumour; an ill-
defined mass which has replaced and permeated myometrium
Figure 3 Case 5. Placental site trophoblastic tumour with some of the cells
positive for human placental lactogen. Immunoperoxidase anti hPL 3 200
Figure 2 Case 5. Placental site trophoblastic tumour cells with abundant
pale eosinophilic cytoplasm and pleomorphic nuclei. There is invasion of
myometrium and permeation of a vessel wall. H & E 3 100It is known that PSTT can follow normal pregnancy, abortion or
hydatidiform mole. Confirmation of the clinical impression of the
ability of PSTT to arise from molar pregnancies or normal concep-
tions is provided by genetic analysis (Fisher et al, 1992). Some
data suggest that a normal female conception is not only a
common antecedent pregnancy but also an independent poor prog-
nostic feature (Finkler, 1991); however, this is not confirmed by
other investigators. In our own series a normal female conception
preceded PSTT in 5/7 cases including the two deaths.
In this series the interval between antecedent pregnancy and
presentation/diagnosis with PSTT was very varied (median 24
months; range 12 months to 15 years). Previous reports have
suggested that a long interval from antecedent pregnancy to
presentation is a significant adverse prognostic variable (Bower et
al, 1996), a finding confirmed by others (Finkler et al, 1988; How
et al, 1995). The common presenting feature was abnormal vaginal
bleeding  ± amenorrhoea; these findings are in agreement with
previous reports (Finkler, 1991; Bower et al, 1996). It would be
wrong to interpret this as evidence of a biologically indolent
tumour – 3/7 of our cases had metastases beyond the female
genital tract at diagnosis.
Histologically PSTT is a tumour with intermediate trophoblast
differentiation, and a pattern of invasion similar to normal interme-
diate trophoblast. The poorly circumscribed mass infiltrates
between muscle fibres and along vessel walls. This is in contrast to
choriocarcinoma which forms a haemorrhagic mass with a charac-
teristic biphasic histology of cytotrophoblast and syncytiotro-
phoblast cells in a bilaminar configuration, and intravascular
growth (Silverberg and Kurman, 1991). Though it is usually
possible to separate these tumours discrete categorization is not
always possible. Case 4 illustrates some of the difficulties; the
histology has been reviewed again by an expert gynaecological
pathologist and was considered to be closer to PSTT than chorio-
carcinoma. The patient was managed as having PSTT, and the case
is included in this series to reflect the realities of caring for patients
with this rare neoplasm.
Our series conforms to the usual pattern of immunohistochem-
ical staining of PSTT, which typically shows a high proportion of
cells positive for hPL, and relatively few positive for hCG, though
about 12–15% of cases have an equal or higher proportion of hCG
(Kurman et al, 1984; Bower et al, 1996). Positive staining of all
cell types for cytokeratins throughout the tumour is the rule, and
helps in the differential diagnosis from connective tissue tumours.
We also confirm the relatively poor predictive value of mitotic
counts. Though our fatal cases both had a relatively high count,
tumours with a low count may metastasize. Sampling variability
within this tumour means that prediction of behaviour from biopsy
specimens is unreliable (Hopkins et al, 1985; Finkler et al, 1998;
Lathrop et al, 1988).
hCG is considered a tumour marker par excellence in evaluating
treatment and follow-up of patients with choriocarcinoma and molar
pregnancies – hCG value correlating with tumour bulk and persis-
tence of disease. Unfortunately the same situation does not apply to
PSTT. In our series the median hCG was 314 iu l–1 with a range of
6–107 600 iu l–1 with no direct correlation between tumour burden
and hCG value. In fact a low hCG estimation in patients with a rela-
tively large tumour burden should cause clinical suspicion of a
PSTT. The low levels of hCG produced by PSTT reflects the cellular
origin of this tumour type – intermediate trophoblast cells produce
little hCG and larger quantities of hPL. In two patients (cases 6 and
7) we measured serum levels of hPL; however, the levels were
barely elevated, did not serve as useful markers of disease activity
and were unhelpful in guiding treatment decisions.
It is clear that the biological behavior of PSTT is variable and
difficult to predict. The first diagnostic and therapeutic interven-
tion is usually surgical. A conservative approach to surgery has
been advocated by some, based on PSTT regressing after curettage
(Kurman et al, 1976; Driscoll, 1984). However, this approach is
probably only of value in younger women who wish to retain their
childbearing potential and who understand that the tumour has
unpredictable behaviour, and that the clinician’s ability to success-
fully monitor that behaviour is currently limited. For other women
with disease confined to the uterus a hysterectomy (with or
without ovarian conservation, depending on risk/benefit analysis
in view of the individual’s age) is a more appropriate surgical
intervention with a high cure rate. In our series 5/7 patients had a
hysterectomy. Of the two who did not, one (case 7) wished to
retain her childbearing capability and the other (case 4) had wide-
spread metastases at diagnosis.
For women with metastases at diagnosis surgical cure is unat-
tainable and systemic chemotherapy is required. In comparison to
other forms of GTD, PSTT is less chemosensitive. Four patients in
our series had metastases at diagnosis; the two patients with metas-
tases confined to the lungs achieved remission with the use of CEC
salvage chemotherapy (see Table 2). This experience is similar to
other reports in the literature (Dessau et al, 1990; King et al, 1992)
and contrasts with initial fears that this tumour may be unrespon-
sive to chemotherapy (Lathrop et al, 1988).
The use of irradiation has been reported in the palliative setting
with some success (Finkler et al, 1988; Wain et al, 1993; Bower
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Table 2 Trophoblastic disease treatment regimens at Weston Park Hospital
Low risk First line Methotrexate 50 mg intramuscular alternate days ´ 4
‘low dose Folinic acid 7.5 mg oral 24 h after methotrexate
methotrexate’ 7-day intervals between cycles
Salvage Dactinomycin 0.5 mg day–1 intravenous ´ 3
‘AE’ Etoposide 100 mg m–2 day–1 intravenous ´ 3
7-day intervals between cycles
High risk First line Arm A: Methotrexate 300 mg m–2 intravenous
‘MAE’ Folinic acid 15 mg 6-h commencing 24 h after methotrexate (eight doses, the first four intravenous)
Alternating with Arm B (‘AE’ as above) with 7-day intervals between each arm
Salvage Cisplatin 25 mg m–2 intravenous daily ´ 3
‘CEC’ Etoposide 100 mg m–2 intravenous daily ´ 3
Cyclophosphamide 600 mg m–2 intravenous day 1
7–10-day intervals between cycles1190 AM Gillespie et al
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et al, 1996). However, the use of irradiation without evidence of
response has also been reported. In our series one patient received
palliative irradiation to cranial metastases – with no evidence of
tumour response.
In conclusion, PSTT is a rare tumour with unpredictable biolog-
ical behaviour – nevertheless it is potentially curable. The diagnosis
should be suspected when hCG levels are low relative to tumour
burden. In the first instance surgery forms the cornerstone of
therapy; however, contemporary practice shows that intensive multi-
agent chemotherapeutic regimens can be used with some success in
some of those with metastatic (particularly pulmonary) disease.
Patients should be managed in Trophoblastic Disease Centres –
where an experienced gynaecological pathologist should review
histological diagnoses. Clinicans and patients should be aware of the
major differences between this and other forms of GTD.
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